Skip to content

WHO issues first guideline on GLP-1 drugs for obesity

2 December 20251 min read
SCIENCE & TECHNOLOGYWHO issues firstguideline on GLP-1drugs for obesity2 December 2025safalsetu.com

Why in the news

The World Health Organization released its first global guideline on GLP-1 therapies for treating obesity in adults. It also warned that high prices and limited supply could widen health inequalities.

Key facts

  • The guideline targets adults with a BMI of 30 or more; pregnant women are excluded.
  • Three medicines are covered: semaglutide, tirzepatide and liraglutide.
  • Use must be combined with a healthy diet and regular physical activity.
  • These medicines achieve around 15-20% weight loss, comparable to bariatric surgery.
  • The guideline makes two conditional recommendations: GLP-1 use for long-term management, and lifestyle change alongside medication.
ItemFigure
People living with obesity worldwideOver 1 billion
Obesity deaths in 20243.7 million
Eligible people likely to get GLP-1 drugs by 2030Under 10%
Projected annual economic cost by 2030USD 3 trillion

About obesity thresholds

WHO defines adult obesity as a BMI of 30 or above, while India uses a lower threshold of 25. NFHS-5 (2019-21) found 24% of women and 23% of men were overweight or obese.

Exam angle

  • Note the three drug names and the BMI cut-off of 30.
  • Access barriers are manufacturing capacity and pricing.
  • Expect statements on the USD 3 trillion cost and the 10% access figure.

Test yourself

1. WHO's first GLP-1 guideline for obesity applies to adults with a BMI of at least:

The guideline targets adults with BMI of 30 or more, excluding pregnant women.

2. Which of these medicines is covered by WHO's GLP-1 obesity guideline?

The guideline covers semaglutide, tirzepatide and liraglutide.

3. WHO warns that by 2030 fewer than what share of eligible people may access GLP-1 therapies?

Access is projected to stay below 10% of eligible people because of limited supply and high prices.

Sources: GKToday: WHO GLP-1, Drishti IAS daily news analysis 02-12-2025